Invention Grant
![Pyrazolo[1,5-A]pyrimidines as mark inhibitors](/docs/US/2015-02-03/US08946237B2/abs.jpg.600x600.jpg)
- Patent Title: Pyrazolo[1,5-A]pyrimidines as mark inhibitors
- Patent Title (中): 吡唑并[1,5-A]嘧啶作为标记抑制剂
-
Application No.: US13521382Application Date: 2011-01-11
-
Publication No.: US08946237B2Publication Date: 2015-02-03
- Inventor: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
- Applicant: Jongwon Lim , Brandon M. Taoka , Sandra Lee , Alan Northrup , Michael D. Altman , David L. Sloman , Matthew G. Stanton , Njamkou Noucti
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Keith D. MacMillan; John C. Todaro
- International Application: PCT/US2011/020739 WO 20110111
- International Announcement: WO2011/087999 WO 20110721
- Main IPC: A01N43/90
- IPC: A01N43/90 ; A61K31/519 ; C07D487/00 ; C07D487/04
![Pyrazolo[1,5-A]pyrimidines as mark inhibitors](/abs-image/US/2015/02/03/US08946237B2/abs.jpg.150x150.jpg)
Abstract:
The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
Public/Granted literature
- US20130210838A1 PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS Public/Granted day:2013-08-15
Information query
IPC分类:
